Lumen Bioscience
Phase 3Lumen’s patented biologic drug platform shortens the development process, reduces costs and risks, and accelerates time-to-market, making us the first company to make orally delivered antibody drugs commercially viable.
Founded
2017
Focus
AntibodiesBiologics
About
Lumen’s patented biologic drug platform shortens the development process, reduces costs and risks, and accelerates time-to-market, making us the first company to make orally delivered antibody drugs commercially viable.
Funding History
4Total raised: $62M
Grant$15MBill & Melinda Gates FoundationOct 15, 2022
Series B$31MAviv VenturesMar 15, 2021
Series A$14MBioGeneration VenturesAug 15, 2019
Seed$2MUndisclosedMay 15, 2017
Company Info
TypePrivate
Founded2017
LocationSeattle, United States
StagePhase 3
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile